+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liver Cancer Drug Market Size, Share & Trends Analysis Report By Drug (Targeted Therapy, Immunotherapy, Chemotherapy), By Type, By Distribution Channel, By Region And Segment Forecasts 2024 - 2030

  • PDF Icon

    Report

  • 100 Pages
  • August 2024
  • Region: Global
  • Grand View Research
  • ID: 5899559
Description Jump to:

Liver Cancer Drug Market Growth & Trends

The global liver cancer drug market size is expected to reach USD 9.81 billion by 2030, registering a CAGR of 17.8% from 2024 to 2030. The growth of liver cancer market is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rising public awareness. Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population. This, in turn, is working in favor of the liver cancer therapeutics market. Therapeutic development in second-line setting for Nexavar-intolerant patients is estimated to have a major impact in the HCC space.

Liver cancer is the fifth most prevalent cancer worldwide and accounts for 9.0% of all cancer deaths. In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer. Primary liver cancer remains an important public health issue due to its extremely aggressive nature and poor survival rate. Hepatocellular carcinomas (HCCs) represents the majority (75-90%) of primary liver cancers. A noteworthy number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, can be modified and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.

Liver Cancer Drug Market Report Highlights

  • The targeted therapy segment held the largest market revenue share of 53.0% in 2023 due to its precision in targeting specific molecules or pathways involved in the growth and spread of cancer cells.
  • Hepatocellular Carcinoma (HCC) dominated the liver cancer drug market with a 36.6% revenue share in 2023. HCC Is the most common type of primary liver cancer.
  • Hospital pharmacy dominated the liver cancer drug market with a revenue share of 45.5% in 2023.
  • North America liver cancer drug market held a revenue share of 42.7% in 2023.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Liver Cancer Drug Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Liver Cancer Drug Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Liver Cancer Drug Market: Drug Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Liver Cancer Drug Market: Drug Movement Analysis, 2018 - 2030 (USD Million)
4.3. Targeted Therapy
4.3.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.1. Bevacizumab
4.3.1.1.1. Bevacizumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.2. Cabozantinib
4.3.1.2.1. Cabozantinib Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.3. Lenvatinib
4.3.1.3.1. Lenvatinib Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.4. Ramucirumab
4.3.1.4.1. Ramucirumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.5. Regorafenib
4.3.1.5.1. Regorafenib Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.6. Sorafenib
4.3.1.6.1. Sorafenib Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.1.7. Other Targeted Therapies
4.3.1.7.1. Other Targeted Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Immunotherapy
4.4.1. Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.1.1. Atezolizumab with Bevacizumab
4.4.1.1.1. Atezolizumab with Bevacizumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.1.2. Nivolumab with Ipilimumab
4.4.1.2.1. Nivolumab with Ipilimumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.1.3. Pembrolizumab
4.4.1.3.1. Pembrolizumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.1.4. Durvalumab with Tremelimumab
4.4.1.4.1. Durvalumab with Tremelimumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.1.5. Other Immunotherapies
4.4.1.5.1. Other Immunotherapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Chemotherapy
4.5.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.1.1. Gemcitabine
4.5.1.1.1. Gemcitabine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.1.2. Oxaliplatin
4.5.1.2.1. Oxaliplatin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.1.3. Cisplatin
4.5.1.3.1. Cisplatin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.1.4. Doxorubicin
4.5.1.4.1. Doxorubicin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.1.5. 5-fluorouracil
4.5.1.5.1. 5-fluorouracil Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.1.6. Capecitabine
4.5.1.6.1. Capecitabine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.1.7. Mitoxantrone
4.5.1.7.1. Mitoxantrone Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.1.8. Other Chemotherapies
4.5.1.8.1. Other Chemotherapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Liver Cancer Drug Market: Type Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Liver Cancer Drug Market: Type Movement Analysis, 2018 & 2030 (USD Million)
5.3. Hepatocellular Carcinoma
5.3.1. Hepatocellular Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Cholangio Carcinoma
5.4.1. Cholangio Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Hepatoblastoma
5.5.1. Hepatoblastoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Liver Cancer Drug Market: Distribution Channel Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Liver Cancer Drug Market: Distribution Channel Movement Analysis, 2018 & 2030 (USD Million)
6.3. Hospital Pharmacy
6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Retail Pharmacy
6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Online Pharmacy
6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Liver Cancer Drug Market: Regional Estimates & Trend Analysis
7.1. Liver Cancer Drug Market Share, By Region, 2023 & 2030 (USD Million)
7.2. North America
7.2.1. North America Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. UK.
7.3.2.1. UK Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Sweden Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Norway Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Japan Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. China
7.4.3.1. China Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Australia Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. South Korea
7.4.6.1. South Korea Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Thailand Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. Saudi Arabia
7.6.2.1. Saudi Arabia Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. UAE
7.6.3.1. UAE Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. South Africa
7.6.4.1. South Africa Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Merck KGaA
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Exelixis, Inc.
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. Eisai Co., Ltd.
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Bristol-Myers Squibb Company.
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Bayer AG
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. Novartis AG
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. F. Hoffmann-La Roche Ltd
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Eli Lilly and Company
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. Pfizer Inc.
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives

Companies Mentioned

  • Exelixis, Inc.
  • Merck KGaA
  • Eisai Co., Ltd.
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Thermo Fisher Scientific Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Bayer AG

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedAugust 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 3.15 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.81 Billion
Compound Annual Growth Rate17.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Liver Cancer Drugs Market by Type, Distribution channel - Global Forecast 2025-2030 - Product Image

Liver Cancer Drugs Market by Type, Distribution channel - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028 - Product Image

United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028

  • Report
  • 88 Pages
  • United States
From
Liver Cancer Drugs - Global Strategic Business Report - Product Image

Liver Cancer Drugs - Global Strategic Business Report

  • Report
  • 277 Pages
  • Global
From
Liver Metastases Treatment Market Size, Share & Trends Analysis Report by Treatment Type (Chemotherapy, Immunotherapy), Primary Cancer, Distribution Channel, Region, and Segment Forecasts, 2024-2030 - Product Image

Liver Metastases Treatment Market Size, Share & Trends Analysis Report by Treatment Type (Chemotherapy, Immunotherapy), Primary Cancer, Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • Report
  • 100 Pages
  • Global
From
Cellular Immunotherapy Market by Type, Indication, Technology Type, End-Use - Global Forecast 2025-2030 - Product Image

Cellular Immunotherapy Market by Type, Indication, Technology Type, End-Use - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.